Terms: = Liver cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Prognosis
948 results:
1. Comprehensive pan-cancer analysis of YBX family reveals YBX2 as a potential biomarker in liver cancer.
Yuan Z; Li B; Liao W; Kang D; Deng X; Tang H; Xie J; Hu D; Chen A
Front Immunol; 2024; 15():1382520. PubMed ID: 38698857
[TBL] [Abstract] [Full Text] [Related]
2. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract] [Full Text] [Related]
3. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
[TBL] [Abstract] [Full Text] [Related]
4. Proteomic analysis of DEN and CCl
Zhang Q; Liu Y; Ren L; Li J; Lin W; Lou L; Wang M; Li C; Jiang Y
Sci Rep; 2024 Apr; 14(1):8013. PubMed ID: 38580754
[TBL] [Abstract] [Full Text] [Related]
5. A prognostic signature established based on genes related to tumor microenvironment for patients with hepatocellular carcinoma.
Cui Z; Li G; Shi Y; Zhao X; Wang J; Hu S; Chen C; Li G
Aging (Albany NY); 2024 Apr; 16(7):6537-6549. PubMed ID: 38579170
[TBL] [Abstract] [Full Text] [Related]
6. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.
Zheng L; Wang Y; Liu Z; Wang Z; Tao C; Wu A; Li H; Xiao T; Li Z; Rong W
Cancer Med; 2024 Apr; 13(7):e7043. PubMed ID: 38572921
[TBL] [Abstract] [Full Text] [Related]
7. Developing risk models and subtypes of autophagy-associated LncRNAs for enhanced prognostic prediction and precision in therapeutic approaches for liver cancer patients.
Zhang LU; Chu J; Yu Y
Oncol Res; 2024; 32(4):703-716. PubMed ID: 38560571
[TBL] [Abstract] [Full Text] [Related]
8. The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy.
Lu W; Wu G; Miao X; Ma J; Wang Y; Xu H; Shentu D; Xue S; Xia Q; Wang Y; Wang L
Cancer Immunol Immunother; 2024 Mar; 73(5):87. PubMed ID: 38554161
[TBL] [Abstract] [Full Text] [Related]
9. prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.
Chen C; Wang C; Li Y; Jiang S; Yu N; Zhou G
Sci Rep; 2024 Mar; 14(1):7157. PubMed ID: 38531953
[TBL] [Abstract] [Full Text] [Related]
10. A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
Zhang S; Qin O; Wu S; Xu H; Huang W; Hailiang S
Aging (Albany NY); 2024 Mar; 16(6):5545-5566. PubMed ID: 38517376
[TBL] [Abstract] [Full Text] [Related]
11. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Value of an Immune Long Non-Coding RNA Signature in liver Hepatocellular Carcinoma.
Kong R; Wang N; Zhou CL; Lu J
J Microbiol Biotechnol; 2024 Apr; 34(4):958-968. PubMed ID: 38494878
[TBL] [Abstract] [Full Text] [Related]
13. Hemochromatosis: Ferroptosis, ROS, Gut Microbiome, and Clinical Challenges with Alcohol as Confounding Variable.
Teschke R
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473913
[TBL] [Abstract] [Full Text] [Related]
14. SPP2 plays a role in the tumorigenesis of hepatocellular carcinoma: A bioinformatic based analysis.
Peng H; Liu Y; Song Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1779-1792. PubMed ID: 38448371
[TBL] [Abstract] [Full Text] [Related]
15. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
[TBL] [Abstract] [Full Text] [Related]
16. Development and evaluation of nomograms and risk stratification systems to predict the overall survival and cancer-specific survival of patients with hepatocellular carcinoma.
Kang X; Liu X; Li Y; Yuan W; Xu Y; Yan H
Clin Exp Med; 2024 Feb; 24(1):44. PubMed ID: 38413421
[TBL] [Abstract] [Full Text] [Related]
17. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma.
Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P
Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539
[TBL] [Abstract] [Full Text] [Related]
18. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract] [Full Text] [Related]
19. High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma.
Tao S; Cui D; Cheng H; Liu X; Jiang Z; Chen H; Gao Y
BMC Cancer; 2024 Feb; 24(1):194. PubMed ID: 38347489
[TBL] [Abstract] [Full Text] [Related]
20. Featured lncRNA-based signature for discriminating prognosis and progression of hepatocellular carcinoma.
Qiu H; Jiang B; Chen Y; Lin Z; Zheng W; Cao X
J Appl Genet; 2024 May; 65(2):355-366. PubMed ID: 38347289
[TBL] [Abstract] [Full Text] [Related]
[Next]
